First-line pembrolizumab alone vs carboplatin/paclitaxel in dMMR advanced or recurrent endometrial cancer: median PFS of 38.2 vs 8.4 months in the phase 3 KEYNOTE-C93 trial.

@GynCancerMD breaks down the #ESMO26 data. 🎥
https://www.targetedonc.com/view/pembrolizumab-alone-exceeds-chemo-first-line-dmmr-endometrial-cancer